Advertisement

Breast Cancer Research and Treatment

, Volume 168, Issue 1, pp 35–41 | Cite as

Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials

  • Filipa LynceEmail author
  • Matthew J. Blackburn
  • Ling Cai
  • Heping Wang
  • Larry Rubinstein
  • Pamela Harris
  • Claudine Isaacs
  • Paula R. Pohlmann
Clinical trial

Abstract

Purpose

Breast cancer (BC) is the most commonly diagnosed cancer and the second leading cause of cancer-related death among women. Given the availability of approved therapies and abundance of phase II and III clinical trials, historically few BC patients have been referred for consideration of participation on a phase I trial. We were interested in determining whether clinical benefit rates differed in patients with BC from other patients enrolled in phase I trials.

Methods

We performed a retrospective analysis of all Cancer Therapy Evaluation Program (CTEP) sponsored phase I trials from 1993 to 2012. We report an analysis of demographic variables, rates of response to treatment, grade 4 toxicities, and treatment-related deaths.

Results

De-identified data from 8087 patients were analyzed, with 1,376 having a diagnosis of BC. The median time from initial cancer diagnosis to enrollment in a CTEP-sponsored phase I clinical trial was 614 days for all patients. Breast cancer patients were enrolled on average 790 days after initial diagnosis, while non-BC patients had a median enrollment time of 582 days (p < 0.001). Breast cancer patients had more clinical responses than non-BC patients (18.3% vs. 4.3%, respectively). Along with the higher rate of response, BC patients remained on phase I trials longer than non-BC patients with a median of 70 days while the latter were on trial for a median of 57 days. The overall rate of death related to the treatment drugs was 0.47%.

Conclusions

Our data confirm our hypothesis that when compared to a general population of patients with cancer enrolled on phase I clinical trials, BC patients tend to derive clinical benefit from these therapies with similar toxicity profile. This evidence further supports enrollment of BC patients on phase I trials.

Keywords

Breast cancer Phase I Clinical trials Outcomes Toxicity 

Abbreviations

AE

Adverse events

BC

Breast cancer

CTCAE

Common terminology criteria for adverse events

CTEP

Cancer therapy evaluation program

CTMS

Clinical trials monitoring service

ECOG

Eastern cooperative oncology group

MBC

Metastatic breast cancer

OS

Overall survival

PIO

Protocol and information office

PS

Performance status

RECIST

Response evaluation criteria in solid tumors

RP2D

Recommended phase 2 dose

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

10549_2017_4563_MOESM1_ESM.docx (90 kb)
Supplementary material 1 (DOCX 89 kb)

References

  1. 1.
    Itoh K, Sasaki Y, Miyata Y et al (1994) Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in Japan. Cancer Chemother Pharmacol 34:451–454CrossRefPubMedGoogle Scholar
  2. 2.
    Estey E, Hoth D, Simon R et al (1986) Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep 70:1105–1115PubMedGoogle Scholar
  3. 3.
    Decoster G, Stein G, Holdener EE (1990) Responses and toxic deaths in phase I clinical trials. Ann Oncol 1:175–181CrossRefPubMedGoogle Scholar
  4. 4.
    Bachelot T, Ray-Coquard I, Catimel G et al (2000) Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 11:151–156CrossRefPubMedGoogle Scholar
  5. 5.
    Han C, Braybrooke JP, Deplanque G et al (2003) Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Br J Cancer 89:1166–1171CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Roberts TG Jr, Goulart BH, Squitieri L et al (2004) Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292:2130–2140CrossRefPubMedGoogle Scholar
  7. 7.
    Sekine I, Yamamoto N, Kunitoh H et al (2002) Relationship between objective responses in phase I trials and potential efficacy of non- specific cytotoxic investigational new drugs. Ann Oncol 13:1300–1306CrossRefPubMedGoogle Scholar
  8. 8.
    Smith TL, Lee JJ, Kantarjian HM et al (1996) Design and results of phase I cancer clinical trials: three-year experience at M.D Anderson Cancer Center. J Clin Oncol 14:287–295CrossRefPubMedGoogle Scholar
  9. 9.
    Von Hoff DD, Turner J (1991) Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 9:115–122CrossRefGoogle Scholar
  10. 10.
    Ganesan P, Moulder S, Lee JJ et al (2014) Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther 13(12):3175–3184CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Horstmann E, McCabe MS, Grochow L et al (2005) Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895–904CrossRefPubMedGoogle Scholar
  12. 12.
    Agus DB, Gordon MS, Taylor C et al (2005) Phase I clinical study of pertuzumab, a novel her dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23:2534–2543CrossRefPubMedGoogle Scholar
  13. 13.
    Phillips GDL, Fields CT, Li G et al (2013) Dual Targeting of HER2 positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res 15 20(2):456–468CrossRefGoogle Scholar
  14. 14.
    Nanda R, Chow QL, Dees EC et al (2016) Pembrolizumab in patients with advanced triple-negative breast cancer: phase ib keynote-012 study. J Clin Oncol 34(21):2460–2467CrossRefPubMedGoogle Scholar
  15. 15.
    Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017
  16. 16.
    Sledge GW, Neuberg D, Bernardo P et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front- line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21:588–592CrossRefPubMedGoogle Scholar
  17. 17.
    Cresta S, Grasselli G, Mansutti M et al (2004) A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Ann Oncol 15(3):433–439CrossRefPubMedGoogle Scholar
  18. 18.
    Conte PF, Guarneri V, Bruzzi P et al (2004) Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer 101:704–712CrossRefPubMedGoogle Scholar
  19. 19.
    Alba E, Martin M, Ramos M et al (2004) Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 22:2587–2593CrossRefPubMedGoogle Scholar
  20. 20.
    Swain SM, Baselga J, Kim S-B et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724–734CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Tejeda HA, Green SB, Trimble EL et al (1996) Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst 88:812–816CrossRefPubMedGoogle Scholar
  22. 22.
    Go RS, Frisby KA, Lee JA et al (2006) Clinical trial accrual among new cancer patients at a community-based cancer center. Cancer 106:426–433CrossRefPubMedGoogle Scholar
  23. 23.
    Postel-Vinay S, Aspeslagh S, Lanoy E et al (2016) Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Ann Oncol 27:214–224CrossRefPubMedGoogle Scholar
  24. 24.
    Ma C, Bandukwala S, Burman D et al (2010) Interconversion of three measures of performance status: an empirical analysis. Eur J Cancer 46(18):3175–3183CrossRefPubMedGoogle Scholar
  25. 25.
    Kurzrock R, Benjamin RS (2005) Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med 352:930–932CrossRefPubMedGoogle Scholar
  26. 26.
    Wheler J, Tsimberidou A, Moulder S et al (2010) Clinical Outcomes of patients with breast cancer in a phase I clinic: the MD Anderson Cancer Center Experience. Clinical Breast Cancer 10(1):46–51CrossRefPubMedGoogle Scholar
  27. 27.
    Verma S, McLeod D, Batist G et al (2011) In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist 16(1):25–35CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    FDA Hematology/Oncology (Cancer) Approvals & Safety Notifications (2015) https://wayback.archive-it.org/7993/20170111231726/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm381452.htm. Accessed on 5 May 2017

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Lombardi Comprehensive Cancer CenterMedStar Georgetown University HospitalWashingtonUSA
  2. 2.University of South Carolina School of MedicineColumbiaUSA
  3. 3.Department of Biostatistics, Bioinformatics, and BiomathematicsGeorgetown UniversityWashingtonUSA
  4. 4.Biometric Research Program, Division of Cancer Treatment and DiagnosisNational Cancer Institute, National Institutes of HealthRockvilleUSA
  5. 5.Investigational Drug Branch Cancer Therapy Evaluation Program Division of Cancer Treatment and DiagnosisNational Cancer Institute, National Institutes of HealthRockvilleUSA
  6. 6.Lombardi Comprehensive Cancer CenterGeorgetown UniversityWashingtonUSA

Personalised recommendations